Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs
- E. Conticini, E. Bargagli, +12 authors B. Frediani
- Annals of the Rheumatic Diseases
- 14 May 2020
It is shown that in a cohort of subjects affected by COVID-19, a low prevalence of patients treated with biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease- modifying antiral drugs (tsDMARDSs) is evidenced. Expand
Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19
Increased KL‐6 serum concentrations were observed in patients with severe pulmonary involvement, revealing a prognostic value and supporting the potential usefulness of KL‐ 6 measurement to evaluate COVID‐19 patients' prognosis. Expand
Postoperative acute kidney injury in lung transplant recipients.
- D. Bennett, A. Fossi, +7 authors P. Rottoli
- Interactive cardiovascular and thoracic surgery
- 1 June 2019
This study confirms the importance of AKI in patients undergoing lung transplant that can significantly affect outcome and particular attention must be paid to the haemodynamics, which proved to be strongly associated with the onset ofAKI. Expand
The pharmacological treatment of bronchiectasis
An overview of aetiopathogenesis, clinics and non-pharmacological management, extending the topic of pharmacological treatment is provided, providing an overview of bronchiectasis and its role in chronic lung diseases. Expand
Lung transplant in patients with familial pulmonary fibrosis.
- D. Bennett, A. Fossi, +6 authors P. Sestini
- Jornal brasileiro de pneumologia : publicacao…
- 27 July 2020
Lung transplant proved to be a valid option for patients with FPF as it was for patientswith other types of pulmonary fibrosis, and short- and long-term outcome was comparable in both groups. Expand
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases
- M. d’Alessandro, A. Carleo, +7 authors E. Bargagli
- Clinical and Experimental Medicine
- 22 January 2020
A panel of BAL biomarkers for diagnosis of ILDs is proposed;CD4 + /CD8 + ratio, KL-6 concentrations, and NK and CD103 + CD4 + cell percentages in BAL could improve the identification and differential diagnosis of sarcoidosis. Expand
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features
- N. Lanzarone, F. Gentili, +13 authors P. Sestini
- Internal and Emergency Medicine
- 20 February 2020
BAL KL-6, a result of alveolar damage, caused in cHP by CD3+ CD8+’mediated flogosis and suggested by radiological evidence of ground-glass opacities and centrilobular nodules, can be considered a useful biomarker to assess, along with BAL cellular analysis and HRCT findings, disease activity. Expand
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib.
Serum KL‐6 levels in pulmonary Langerhans’ cell histiocytosis
- M. d’Alessandro, L. Bergantini, +5 authors E. Bargagli
- European journal of clinical investigation
- 20 April 2020
Serum Krebs von den Lungen‐6 (sKL‐6) is an high‐molecular‐weight (200 kDa) glycoprotein predominantly expressed by damaged alveolar type II cells, and it has been proposed as a potential biomarker of… Expand
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review.
KL-6 levels differentiated between fibrotic ILD, such as idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis, and nonfibrotic lung disorders, including sarcoidosis and pulmonary alveolar proteinosis. Expand